Clinical trial
A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (Obecabtagene Autoleucel [Obe-cel]) in Pediatric Patients With CD19-positive Relapsed/Refractory (R/R) B Cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL).
NCT06173518 is registered in ClinicalTrials.gov with Autolus Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (Obecabtagene Autoleucel [Obe-cel]) in Pediatric Patients With CD19-positive Relapsed/Refractory (R/R) B Cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL).
- Lead sponsor
- Autolus Limited
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- November 16, 2023
- Completion date
- November 30, 2027
- Enrollment
- 30 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory b cell acute lymphoblastic leukemia, relapsed or refractory b cell non-hodgkin lymphoma